Analysis of chemotherapy efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p)
| Autor: | David Humberto Marmolejo Castañeda, Alex Martinez-Marti, Caterina Carbonell, Juan David Assaf Pastrana, Julia Lostes, A. Pedrola, Ramon Amat, N. Pardo, Susana Cedres Perez, Javier Gonzalo, A. Callejo, Rodrigo Dienstmann, Alejandro Navarro, Enriqueta Felip, P. Iranzo, Joan Frigola |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 39:e20563-e20563 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | e20563 Background: MPM is a highly aggressive pleural tumor associated with asbestos exposure and with limited survival despite systemic therapy. Histology is a prognostic factor and recently CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line with some differences in the efficacy of chemotherapy according to histology. However, randomized trials who led to the approval of antifolate in mesothelioma did not include analysis of outcomes by histology. The objective of this study is to characterize the impact of chemotherapy according to histology in p with MPM at our institution. Methods: We review 189 MPM p diagnosed at Vall d´Hebron University Hospital between November 2002 and April 2020. Associations between clinical variables and outcome were assessed with Cox regression models and survival data were calculated by the Kaplan-Meier method. Results: Patient’s characteristics: median age 68 years (y) (45-88 y), males: 70%, performance status (PS)1: 69%, asbestos exposure: 75%, epithelioid subtype: 76%. First line chemotherapy was offered to 85% of p (66% cisplatin-pemetrexed and 27% carboplatin-pemetrexed). Median overall survival (OS) in overall population was 21.3 m (95%CI17.2-24.3). Epithelioid histology, PS 0, neutrophil-lymphocyte ratio |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|